Precision Health Clinical Trials

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

Conditions:   Carcinoma, Squamous Cell;   Carcinoma, Squamous;   Squamous Cell Carcinoma;   Lung Neoplasms;   Cancer of Lung;   Cancer of the Lung;   Lung Cancer;   Neoplasms, Lung;   Neoplasms, Pulmonary;   Pulmonary Cancer;   Pulmonary Neoplasms
Intervention:   Genetic: DNA Extraction
Sponsor:   Mayo Clinic

Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells

Condition:   Healthy
Intervention:   Other: non
Sponsor:   Hadassah Medical Organization
Not yet recruiting

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

Conditions:   Amyloidosis;   Primary Amyloidosis
Sponsor:   Tufts Medical Center

5-HT3 Antagonists (Antiemetics) and Cardiac Safety

Condition:   Adverse Reaction to Other Drugs and Medicines
Intervention:   Drug: Ondansetron
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)

The Vanderbilt Atrial Fibrillation Ablation Registry

Condition:   Atrial Fibrillation
Sponsor:   Vanderbilt University

Analysis of Human Genomic DNA in Embryo's Culture Media

Condition:   Single-Gene Disease
Intervention:   Genetic: Polymerase Chain Reaction and Whole Genome Amplification
Sponsor:   Cervesi Hospital, Cattolica, Italy

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Condition:   Malignant Neoplasm
Interventions:   Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
Sponsor:   Sameek Roychowdhury

Cerebellar Mutism Syndrome Study

Conditions:   Infratentorial Neoplasms;   Mutism
Sponsors:   Rigshospitalet, Denmark;   Odense University Hospital;   Aarhus University Hospital;   Aalborg University Hospital;   Technical University of Denmark;   Karolinska University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   Uppsala University Hospital;   Sahlgrenska University Hospital, Sweden;   University Hospital, Umeå;   Oslo University Hospital;   Trondheim University Hospital;   Haukeland University Hospital;   University Hospital of North Norway;   Helsinki University Central Hospital;   Tampere University Hospital;   Kuopio University Hospital;   Turku University Hospital;   Oulu University Hospital;   Radboud University;   Liverpool University Hospitals NHS Foundation Trust;   Great Ormond Street Hospital for Children NHS Foundation Trust;   Nottingham University Hospitals NHS Trust;   University Hospital Birmingham;   University Hospitals Bristol and Weston NHS Foundation Trust;   Royal Infirmary of Edinburgh;   South Glasgow University Hospitals NHS Trust;   University Hospital Tuebingen

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

Condition:   Triple Negative Breast Cancers Without Lymph-node Involvement and Intervention:   Procedure: Blood samples of 10 mL
Sponsor:   Institut Claudius Regaud

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Genetic: mutation analysis;   Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
Sponsor:   Stanford University